Nurix Therapeutics (NASDAQ:NRIX) CFO Houte Hans Van Sells 4,761 Shares

Nurix Therapeutics, Inc. (NASDAQ:NRIX) CFO Houte Hans Van sold 4,761 shares of the firm’s stock in a transaction that occurred on Tuesday, August 4th. The shares were sold at an average price of $24.36, for a total transaction of $115,977.96. Following the completion of the sale, the chief financial officer owned 40,166 shares in the company, valued at approximately $978,443.76. The trade was a 10.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Houte Hans Van also recently made the following trade(s):

• On Thursday, July 30th, Houte Hans Van sold 2,845 shares of Nurix Therapeutics stock. The shares were sold at an average price of $23.38, for a total transaction of $66,516.10.

Nurix Therapeutics Price Performance

NRIX stock opened at $25.12 on Thursday. The company has a 50 day simple moving average of $20.95 and a 200 day simple moving average of $17.96. The stock has a market cap of $2.61 billion, a price-to-earnings ratio of -7.28 and a beta of 1.79. Nurix Therapeutics, Inc. has a 1 year low of $8.19 and a 1 year high of $25.40.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings data on Thursday, July 9th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.08). The company had revenue of $9.04 million during the quarter, compared to the consensus estimate of $15.29 million. Nurix Therapeutics had a negative net margin of 928.44% and a negative return on equity of 76.09%. On average, equities research analysts anticipate that Nurix Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of NRIX. Larson Financial Group LLC grew its position in shares of Nurix Therapeutics by 339.0% in the 4th quarter. Larson Financial Group LLC now owns 1,541 shares of the company’s stock valued at $29,000 after buying an additional 1,190 shares during the last quarter. Intesa Sanpaolo Wealth Management bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $31,000. Caitong International Asset Management Co. Ltd acquired a new position in shares of Nurix Therapeutics in the fourth quarter worth approximately $33,000. KBC Group NV acquired a new position in shares of Nurix Therapeutics in the first quarter worth approximately $34,000. Finally, Wexford Capital LP bought a new stake in Nurix Therapeutics in the third quarter valued at approximately $41,000.

Wall Street Analyst Weigh In

NRIX has been the topic of a number of research reports. Wall Street Zen upgraded Nurix Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, July 12th. UBS Group increased their target price on Nurix Therapeutics from $23.00 to $31.00 and gave the company a “buy” rating in a research report on Wednesday, July 22nd. Needham & Company LLC reissued a “buy” rating and set a $34.00 price target on shares of Nurix Therapeutics in a research note on Tuesday. BTIG Research restated a “buy” rating and set a $32.00 price target on shares of Nurix Therapeutics in a report on Friday, July 10th. Finally, Oppenheimer initiated coverage on shares of Nurix Therapeutics in a report on Monday, June 29th. They issued an “outperform” rating and a $28.00 price objective for the company. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Nurix Therapeutics presently has an average rating of “Moderate Buy” and an average target price of $34.00.

Nurix Therapeutics News Roundup

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Nurix will receive a $10 million milestone payment after Sanofi initiated a Phase 1 trial of the oral STAT6 degrader SAR448272/NX-3911 for type 2 inflammatory diseases. The company has earned approximately $139 million from the Sanofi collaboration and remains eligible for about $453 million in additional milestones, plus potential royalties and a U.S. co-development option. Nurix Announces $10 Million Milestone Payment
• Positive Sentiment: The company enrolled the first patient in the registrational Phase 3 DAYBreak CLL-306 trial of bexobrutideg in relapsed or refractory chronic lymphocytic leukemia and small lymphocytic lymphoma. The study is designed to test whether bexobrutideg can outperform pirtobrutinib, a key step toward potential regulatory approval and commercialization. Nurix Announces Phase 3 DAYBreak CLL-306 Enrollment
• Positive Sentiment: Needham reaffirmed its Buy rating and maintained a $34 price target, implying substantial upside from the referenced share price. The endorsement reflects continued analyst confidence in Nurix’s pipeline and commercial potential. Needham Rating Update
• Negative Sentiment: Insiders reported additional sales: CFO Hans van Houte sold 4,761 shares for approximately $116,000, while Gwenn Hansen sold 8,467 shares across August 4–5 for roughly $209,000. The transactions were conducted under pre-arranged Rule 10b5-1 plans, reducing their significance as a bearish signal, but they still represent some near-term insider selling pressure.

Nurix Therapeutics Company Profile

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.